These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
642 related articles for article (PubMed ID: 25800784)
1. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Lim YS; Yoo BC; Byun KS; Kwon SY; Kim YJ; An J; Lee HC; Lee YS Gut; 2016 Jun; 65(6):1042-51. PubMed ID: 25800784 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179 [TBL] [Abstract][Full Text] [Related]
3. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419 [TBL] [Abstract][Full Text] [Related]
4. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946 [TBL] [Abstract][Full Text] [Related]
5. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study. Yuan G; Hu C; Zhou Y; Liu J; Huang H; Li Y; Yang D; Zhou F; Zhang YY; Zhou Y Br J Clin Pharmacol; 2017 Oct; 83(10):2259-2265. PubMed ID: 28511283 [TBL] [Abstract][Full Text] [Related]
6. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial. Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380 [TBL] [Abstract][Full Text] [Related]
7. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant. Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368 [No Abstract] [Full Text] [Related]
8. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
9. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Park JG; Park SY Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy. Kim JH; Ahn SH; Ko SY; Choe WH; Kim KH; Kwon SY Clin Mol Hepatol; 2016 Jun; 22(2):241-9. PubMed ID: 27304549 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545 [TBL] [Abstract][Full Text] [Related]
13. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460 [TBL] [Abstract][Full Text] [Related]
14. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235 [TBL] [Abstract][Full Text] [Related]
15. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721 [TBL] [Abstract][Full Text] [Related]
17. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997 [TBL] [Abstract][Full Text] [Related]
19. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. Shao J; Liu Y; Liu LM; Chen R; Zhao L; Zhou Y; Li L; Li X; Li J; Xu D J Infect Dev Ctries; 2021 Jan; 15(1):131-140. PubMed ID: 33571155 [TBL] [Abstract][Full Text] [Related]
20. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. Kim BG; Jung SW; Kim EH; Kim JH; Park JH; Sung SJ; Park BR; Kim MH; Kim CJ; Lee BU; Park JH; Jeong ID; Bang SJ; Shin JW; Park NH J Gastroenterol Hepatol; 2015 Oct; 30(10):1514-21. PubMed ID: 25973716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]